OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
January 24, 2024
Takeda has received FDA approval for HYQVIA, a subcutaneous immunoglobulin for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy.
January 16, 2024
Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.
Webinar Date/Time: Wed, Mar 6, 2024 2:00 PM EST
Webinar Date/Time: Wed, Feb 28, 2024 11:00 AM EST
January 12, 2024
Webinar Date/Time: Wed, Feb 7, 2024 10:30 AM CET (4:30 AM EST)
January 11, 2024
Regulators from around the world will gather to help shape the mRNA and RNA therapeutics landscape at an exceptional April 2024 Washington, D.C. convocation.
January 10, 2024
Nanoform has completed the First Subject First Visit in a trial evaluating the relative bioavailability of its nanotechnology-enhanced enzalutamide.
January 09, 2024
In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates.
January 08, 2024
Webinar Date/Time: Tue, Jan 30, 2024 9:00 AM EST
Webinar Date/Time: Thu, Jan 25, 2024 11:00 AM EST